BRIEF-Initial Data Shows 100% Disease Control in 5 of 5 Patients With Recurrent Glioblastoma Treated With ImmunityBio’s ANKTIVA, NK Cell Therapy Plus Optune Gio Device
Reuters
Aug 26
BRIEF-Initial Data Shows 100% Disease Control in 5 of 5 Patients With Recurrent Glioblastoma Treated With ImmunityBio’s ANKTIVA, NK Cell Therapy Plus Optune Gio Device
Aug 26 (Reuters) - Immunitybio Inc IBRX.O:
INITIAL DATA SHOWS 100% DISEASE CONTROL IN 5 OUT OF 5 PATIENTS WITH RECURRENT GLIOBLASTOMA WITH TWO PATIENTS IN NEAR COMPLETE RESPONSE TREATED WITH IMMUNITYBIO’S ANKTIVA®, NK CELL THERAPY PLUS OPTUNE GIO® DEVICE
Source text: ID:nBw5hkxPDa
Further company coverage: IBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.